Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Study Finds Low Incidence of Intracranial Bleeding With Preventive Low-Dose Aspirin

The protective effect of low-dose aspirin against ischemic cardiovascular (CV) events and colorectal cancer (CRC) appears to outweigh the risks of major bleeding, including...

Randomized Study of Darbepoetin Alfa Shows Modest Reduction in RBC Transfusions in Patients With...

Treatment with the erythropoiesis-stimulating agent (ESA) darbepoetin alfa can reduce the need for red blood cell (RBC) transfusions in patients with lower-risk myelodysplastic syndromes...

High-Dose Chemotherapy Plus Transplantation Improves PFS, But Not OS, in Myeloma Patients

High-dose chemotherapy plus autologous hematopoietic cell transplantation (AHCT) has long been a standard treatment of multiple myeloma (MM), but the associated toxicity risks and...

Pembrolizumab Safe and Effective in Heavily Pretreated Patients With Classic Hodgkin Lymphoma

Though the standard of care for patients with relapsed/refractory classic Hodgkin lymphoma (cHL) induces high rates of response, duration of response is estimated to...

Adding Eltrombopag to Immunosuppression Improves Hematologic Response in Patients With Severe Aplastic Anemia

Acquired aplastic anemia (AA), which results from immune-mediated destruction of the bone marrow, can often be treated with immunosuppressive therapies. Whether the efficacy of...

Blinatumomab Versus Standard-of-Care Chemotherapy in Acute Lymphocytic Leukemia

In a multinational, prospective, randomized, phase III study, investigators found that the anti-CD19/CD3 bispecific T-cell engager antibody blinatumomab improved survival outcomes, compared with standard-of-care...

Pomalidomide Does Not Significantly Improve RBC Transfusion Needs in Myelofibrosis

Anemia occurs commonly in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF), and such patients are often red blood cell (RBC) transfusion-dependent. No therapy approved...

Finding the Best VTE Prophylaxis Options for Patients Undergoing Total Hip and Knee Replacement

For prophylaxis against venous thromboembolism (VTE) after total hip replacement (THR) or total knee replacement (TKR), guidelines from the American College of Chest Physicians...

Long-Term Follow-Up Confirms Safety, Efficacy of Imatinib for CML

Early results (published in Leukemia in 2009) from the phase III International Randomized Study of Interferon and STI571 (IRIS) demonstrated that imatinib 400 mg...

Deep Response With Venetoclax Plus Rituximab in Relapsed/Refractory CLL

Combining the selective BCL2 inhibitor venetoclax with rituximab may increase the depth and durability of response in patients with relapsed/refractory chronic lymphocytic leukemia (CLL),...
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.